Anavex 2-73 Slows Cognitive Decline in Alzheimer’s Patients, Phase 2 Extension Trial Shows

Anavex 2-73 Slows Cognitive Decline in Alzheimer’s Patients, Phase 2 Extension Trial Shows
Treatment with Anavex's investigational therapy Anavex 2-73 significantly reduces cognitive decline in people with Alzheimer’s disease and sustains their ability to perform daily activities, according to interim data from a Phase 2 extension study. Trial results were presented in a late-breaking oral presentation, titled “Longitudinal 148-Week Extension Study for ANAVEX®2-73 Phase 2a Alzheimer’s Disease Demonstrates Maintained Activities of Daily Living Score (ADCS-ADL) and Reduced Cognitive Decline (MMSE) for Patient Cohort on Higher Drug Concentration and Confirms Role of Patient Selection Biomarkers,” at the recent 11th Clinical Trials on Alzheimer’s Disease (CTAD) meeting in Barcelona, Spain. Anavex 2-73 is an investigational therapy that binds to and activates a cellular receptor called Sigma-1 (SIGMAR1), known to have neuroprotective effects. SIGMAR1 activation results in reduced neuroinflammation, accumulation of beta-amyloid and tau proteins, and oxidative stress, features known to be involved in Alzheimer’s disease and other neurodegenerative disorders. Results from a randomized, open-label Phase 2 trial (NCT02244541) showed that one year of treatment with 30mg or 50 mg of oral Anavex 2-73 was safe and prevented further cognitive decline in 32 people with mild to moderate Alzheimer’s. Researchers also conducted a detailed molecular analysis on t
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *